Skip to main navigation
Skip to main content
Skip to Footer
US
Sandoz Site Directory
Home
Our Work
What We Do
Disease Areas
Quality Generics
Biosimilars
Partnerships and Collaborations
Access to Healthcare
About Us
Who We Are
Corporate Responsibility
Investor Information
Contact Us
Doing Business Responsibly
Patients & Customers
Report Side Effects
Product Safety Notices
Information for Customers
Products
Sandoz Patient Assistance
News
US Press Releases & News
Media Contacts
Publications
Careers
Job Search
Working at Sandoz US
Diversity & Inclusion
Search
All News
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Featured News
Media Releases
In the News
Filter By
2016
December
Media Release
/
Dec 05, 2016
New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product
Read More
November
Media Release
/
Nov 22, 2016
Sandoz to donate up to USD 10 million of high-quality generic medicines annually to Americares to increase access to medicines
Read More
August
Media Release
/
Aug 31, 2016
AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment
Read More
Media Release
/
Aug 30, 2016
FDA approves Sandoz Erelzi™ to treat multiple inflammatory diseases
Read More
Media Release
/
Aug 18, 2016
Launch of novel on-demand news service Transplant TODAY from TTS 2016 transplant congress
Read More
July
Media Release
/
Jul 21, 2016
Sandoz launches generic version of Crestor®
Read More
Media Release
/
Jul 13, 2016
Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases
Read More
Media Release
/
Jul 07, 2016
New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product
Read More
June
Media Release
/
Jun 20, 2016
Sandoz announces plans for five major global biosimilar launches by 2020
Read More
2015
November
Media Release
/
Nov 12, 2015
Generic medicines saved US healthcare system more than USD 250 billion in 2014 alone
Read More
Twitter
Tweet
Facebook
Share
Share
Twitter
Facebook
LinkedIn
Email
Jump to Comments
Print
Save
You are here
Home
›
News
›
